An observational study in Bipolar Disorder, sponsored by Jennifer Sweet. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Jennifer Sweet · Observational
The goal of this cross-sectional study is to use diffusion-weighted imaging based tractography (DWT) to assess white matter (WM) pathways in treatment-refractory bipolar disorder (REF-BD) and treatment responsive bipolar disorder (RSP-BD) subjects compared to healthy controls (HCs). This project will include a prospective controlled trial to include 50 subjects with REF-BD, 50 patients RSP-BD and 50 healthy volunteers.
1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.
This study's enrollment of 26 is below the median of 160 across 329 observational studies indexed under Bipolar Disorder.
Browse Bipolar Disorder studies →This is the only study on the registry with Jennifer Sweet as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Participants from all three groups will be made up of those who respond to IRB approved advertisements or are referred by a provider within the UHCMC Department of Psychiatry or other provider referral.
Group 1: Healthy Volunteers
Inclusion Criteria for Group 1:
Exclusion Criteria for Group 1:
Group 2: Treatment-Responsive BDI
Inclusion Criteria for Group 2:
Exclusion Criteria for Group 2:
Group 3: Treatment-Refractory BDI
Inclusion Criteria for Group 3:
Exclusion Criteria for Group 3:
These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
Other: Magnetic Resonance Imaging
This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
Other: Magnetic Resonance Imaging · Other: Psychiatric testing · Other: Eye-Tracking · Other: Neuropsychology Evaluation
This group will be composed of participants who have BDI or BDII, are currently depressed or manic with their current episode lasting at least 6months and not responding to 2 or more adequate evidence-based treatments for BDI or BDII.
Other: Magnetic Resonance Imaging · Other: Psychiatric testing · Other: Eye-Tracking · Other: Neuropsychology Evaluation
Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
Subjects will be evaluated using psychiatric assessments
Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
Characterize white matter (WM) connectivity with DWT to identify an anatomical substrate for BD that has future potential as a therapeutic target
The imaging visit will consist of an MRI with diffusion-weighted imaging (DWI) sequences
Time frame: Day 1
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.